Journal Information
Vol. 45. Issue 11.
Pages 572-573 (November 2009)
Share
Share
Download PDF
More article options
Vol. 45. Issue 11.
Pages 572-573 (November 2009)
Letters to the Editor
Full text access
Pulmonary Toxicity Associated With Cabergoline
Toxicidad pulmonar por medicamentos inducida por cabergolina
Visits
5879
Huseyin Ozkurta,
Corresponding author
drhozkurt@yahoo.com

Corresponding author.
, Oznur Tufanera, Cihangir Gorgulub
a Departamento de Radiología, Hospital para la Docencia y la Investigación Sisli Etfal, Estambul, Turkey
b Centro de Radiología Fulya, Estambul, Turkey
This item has received
Article information
Full text is only aviable in PDF
References
[1.]
S.J. Ellis, J.R. Cleverley, N.L. Müler.
Drug-induced lung disease, high-resolution CT findings.
AJR Am J Roentgenol, 175 (2000), pp. 1019-1024
[2.]
J.R. Graham, H.I. Suby, P.R. LeCompte, N.L. Sadowsky.
Fibrotic disorders associated with methysergide therapy for headache.
N Engl J Med, 274 (1966), pp. 359-368
[3.]
P. Pfitzenmeyer, P. Foucher, G. Dennewald, B. Chevalon, D. Debieuvre, P. Bensa, et al.
Pleuropulmonary changes induced by ergoline drugs.
Eur Respir J, 9 (1996), pp. 1013-1019
[4.]
A. Colao, G. Lombardi, L. Annunziato.
Cabergoline.
Expert Opin Pharmacother, 1 (2000), pp. 555-574
[5.]
S. Guptha, A.D. Promnitz.
Pleural effusion and thickening due to cabergoline use in a patient with Parkinson's disease.
Eur J Intern Med, 16 (2005), pp. 129-131
[6.]
C. Villavicencio, A. Ramírez-Sarmiento, A. Gayete, S. Grau, M. Orozco-Levi.
Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug.
Arch Bronconeumol, 43 (2007), pp. 519-522
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?